What Will Happen to Bristol-myers Squibb Company (NYSE:BMY) Next? The Stock Has Decline in Shorts

May 18, 2018 - By Eva Godbolt

Bristol-Myers Squibb Company (NYSE:BMY) Logo

Investors sentiment decreased to 0.94 in Q4 2017. Its down 0.09, from 1.03 in 2017Q3. It is negative, as 72 investors sold Bristol-Myers Squibb Company shares while 526 reduced holdings. 106 funds opened positions while 457 raised stakes. 1.11 billion shares or 0.48% more from 1.11 billion shares in 2017Q3 were reported.
Moreover, Jane Street Grp Llc has 0.01% invested in Bristol-Myers Squibb Company (NYSE:BMY). Maryland Mgmt owns 18,142 shares or 0.16% of their US portfolio. Srb owns 0.02% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 3,111 shares. The Pennsylvania-based Staley Capital Advisers has invested 0.03% in Bristol-Myers Squibb Company (NYSE:BMY). Sheets Smith Wealth Management invested in 16,139 shares. State Of Wisconsin Inv Board has 2.24 million shares. Clear Harbor Asset Mngmt Ltd owns 7,737 shares or 0.09% of their US portfolio. Cetera Advisor Netwr Ltd Limited Liability Company holds 0.15% or 60,343 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 363,564 shares or 0.2% of its portfolio. Highlander Capital Management Ltd Com holds 5,424 shares. Parametrica Mngmt owns 3,432 shares for 0.13% of their portfolio. Park Corp Oh has 46,303 shares. Moreover, Terril Brothers has 9.54% invested in Bristol-Myers Squibb Company (NYSE:BMY). Meeder Asset Mngmt Inc reported 59,503 shares. Newman Dignan And Sheerar accumulated 30,650 shares.

Since December 12, 2017, it had 2 insider buys, and 1 sale for $163,963 activity. Samuels Theodore R. II bought $249,187 worth of Bristol-Myers Squibb Company (NYSE:BMY) on Friday, December 15. Paliwal Dinesh C bought 4,770 shares worth $249,948.

The stock of Bristol-myers Squibb Company (NYSE:BMY) registered a decrease of 11.21% in short interest. BMY’s total short interest was 12.71 million shares in May as published by FINRA. Its down 11.21% from 14.32 million shares, reported previously. With 15.99M shares average volume, it will take short sellers 1 days to cover their BMY’s short positions. The short interest to Bristol-myers Squibb Company’s float is 0.78%.

The stock increased 1.02% or $0.53 during the last trading session, reaching $52.74. About 8.10M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since May 18, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $86.23 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 86.46 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 11 analysts covering Bristol Myers (NYSE:BMY), 4 have Buy rating, 0 Sell and 7 Hold. Therefore 36% are positive. Bristol Myers had 17 analyst reports since February 6, 2018 according to SRatingsIntel. On Friday, February 16 the stock rating was maintained by Citigroup with “Buy”. Jefferies maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, April 13 with “Hold” rating. As per Wednesday, February 28, the company rating was downgraded by DZ Bank. The rating was maintained by Cowen & Co with “Hold” on Friday, April 20. BMO Capital Markets upgraded the shares of BMY in report on Friday, April 27 to “Market Perform” rating. As per Wednesday, April 18, the company rating was maintained by BMO Capital Markets. On Tuesday, February 6 the stock rating was maintained by BMO Capital Markets with “Underperform”. Bank of America maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Tuesday, April 17. Bank of America has “Neutral” rating and $61 target. Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE:BMY) on Thursday, February 15 to “Overweight” rating. Jefferies maintained the shares of BMY in report on Monday, February 26 with “Hold” rating.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Fool.com which released: “Why Bristol-Myers Squibb Stock Crashed in April” on May 09, 2018, also Streetinsider.com with their article: “Bristol-Myers (BMY) option implied volatility flat, to present immuno-oncology-based research at ASCO” published on May 17, 2018, Streetinsider.com published: “Morgan Finds Positive Datapoints For MRK and BMY At ASCO” on May 17, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Bizjournals.com and their article: “How Bristol-Myers Squibb’s new Peninsula digs boost its battle to beat cancer” published on May 01, 2018 as well as Seekingalpha.com‘s news article titled: “Jounce down 32% premarket on announcement of trial data on lead candidate JTX-2011” with publication date: May 17, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: